An observational study in Triglycerides Glucose Index, Angiographic Profiling and Non-Diabetic, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Premature Birth with a site in Egypt — 17 open to participants now, 18 under way, 4 of them phase 3. Premature Birth · Egypt.
Among the 78 studies in Premature Birth with a site in Egypt, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2025, is one of 16 observational ones, reaches primary completion later than 9 of the 17 other live ones, and was the 72nd registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →17 of the 78 studies in Premature Birth with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–45 · Women only
Ain Shams University · Sites in Egypt
Ages 1 days–1 mo
Jouf University · Sites in Egypt
Ages 18+
Alexandria University · Sites in Egypt
Ages 3 days–1 mo
Alexandria University · Sites in Egypt
Ages 1 min–2 min · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 9 · Phase 3 8 · Phase 4 12
First in 2009; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 85 across the 62 interventional studies, 100 across the 16 observational. Of the 46 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 78 has an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 2 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
2 of the studies in Premature Birth with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07926009Ain Shams UniversityNAVA Use in Preterm Neonates With Respiratory Distress Syndrome | 2027-10 |
| NCT07916142Sohag UniversityEffect of Antenatal Dexamethasone on Postnatal Adrenal Hormones in Preterm Neonates | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies in Premature Birth with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).
Premature coronary artery disease (CAD), defined as CAD occurring before the age of 55 in men and 65 in women, has emerged as a growing health concern worldwide.
Insulin resistance and associated metabolic alterations are strongly implicated in premature atherosclerosis. Even in non-diabetic individuals, subclinical insulin resistance promotes endothelial dysfunction, oxidative stress, and low-grade inflammation, leading to early vascular damage.
The triglyceride-glucose (TyG) index, calculated using fasting glucose and triglyceride levels, has emerged as a cost-effective surrogate marker for insulin resistance.
This cross-sectional study will be conducted at Sohag University Hospitals, following approval from the institutional ethics committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a low triglyceride-glucose (TyG) index tertile.
Other: Coronary Angiographic Assessment
Patients with a high triglyceride-glucose (TyG) index tertile.
Other: Coronary Angiographic Assessment
Coronary angiographic assessment will be performed for all patients.
Incidence of ischemia- driven revascularization
Incidence of ischemia- driven revascularization will be recorded.
Time frame: 6 months post-procedure
Association between triglyceride-glucose index and single-vessel disease
The association between the triglyceride-glucose (TyG) index and single-vessel disease (SVD) will be recorded.
Time frame: 6 months post-procedure
Association between triglyceride-glucose index and two-vessel disease
The association between the triglyceride-glucose index (TyG) and two-vessel disease (2VD) will be recorded.
Time frame: 6 months post-procedure
Association between triglyceride-glucose index and three-vessel disease
The association between the triglyceride-glucose index (TyG) and three-vessel disease (3VD) will be recorded.
Time frame: 6 months post-procedure
Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor
Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor will be recorded.
Time frame: 6 months post-procedure
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.